Stock FRTX FRESH TRACKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Fresh Tracks Therapeutics, Inc. Share Price

Equities

FRTX

US10802T2042

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 18:02:54 26/04/2024 BST 		5-day change 1st Jan Change
0.9101 USD -1.14% Intraday chart for Fresh Tracks Therapeutics, Inc. +1.09% +3.53%
03-15 Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index CI

Financials

Sales 2022 6.94M 556M Sales 2023 8.01M 641M Capitalization 5.25M 420M
Net income 2022 -21M -1.68B Net income 2023 -5M -400M EV / Sales 2022 -0.59 x
Net cash position 2022 8.63M 691M Net cash position 2023 10.87M 870M EV / Sales 2023 -0.7 x
P/E ratio 2022
-0.2 x
P/E ratio 2023
-0.83 x
Employees 4
Yield 2022 *
-
Yield 2023
-
Free-Float 98.4%
More Fundamentals * Assessed data

Chart Fresh Tracks Therapeutics, Inc.

Dynamic Chart

Latest news about Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision MT
Top Premarket Gainers MT
Fresh Tracks Therapeutics' Board Approves Liquidation Plan; Shares Rise After Hours MT
Fresh Tracks Therapeutics, Inc. Announces Chief Executive Officer Changes CI
Fresh Tracks Therapeutics, Inc. Announces Executive Changes CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately CI
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q1 Revenue $9,000 MT
More news

Analyst Recommendations on Fresh Tracks Therapeutics, Inc.

Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision MT
Oppenheimer Adjusts Fresh Tracks Therapeutics Price Target to $4 From $9, Maintains Outperform Rating MT
Oppenheimer Adjusts Price Target on Fresh Tracks Therapeutics to $9 From $1, Maintains Outperform Rating MT
HC Wainwright Adjusts Brickell Biotech's Price Target to $4.50 From $2, Keeps Buy Rating MT
More recommendations

Press releases Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics : Termination of Material Agreement - Form 8-K PU
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th AQ
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th AQ
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market AQ
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th AQ
More press releases

News in other languages on Fresh Tracks Therapeutics, Inc.

MÄRKTE USA/Uneinheitlich - Zinspfad ungewiss
MÄRKTE USA/Uneinheitlich - Zinssorgen bleiben präsent
MÄRKTE USA/Wall Street mit leichter Erholung
MÄRKTE USA/Wall Street stabilisiert nach Vortagesverlusten
MARKT USA/Wall Street stabilisiert nach Vortagesverlusten
More news

Quotes and Performance

1 day-1.14%
1 week+1.09%
Current month+0.62%
1 month+3.16%
3 months-7.13%
6 months-1.08%
Current year+3.53%
More quotes

Highs and lows

1 week
0.90
Extreme 0.9001
0.93
1 month
0.87
Extreme 0.8741
0.95
Current year
0.86
Extreme 0.86
1.01
1 year
0.45
Extreme 0.4495
1.10
3 years
0.45
Extreme 0.4495
49.05
5 years
0.45
Extreme 0.4495
225.00
10 years
0.45
Extreme 0.4495
225.00
More quotes

Managers and Directors - Fresh Tracks Therapeutics, Inc.

Managers TitleAgeSince
Albert Marchio CEO
 Chief Executive Officer 72 30/11/20
Nancy Seretta CTO
 Chief Tech/Sci/R&D Officer - 31/12/15
Aaron Fox-Collis AUD
 Comptroller/Controller/Auditor - 30/06/20
Members of the board TitleAgeSince
Albert Marchio CEO
 Chief Executive Officer 72 30/11/20
More insiders

Quotes

Date Price Change Volume
26/04/24 0.9101 -1.14% 795
25/04/24 0.9206 -1.01% 422
24/04/24 0.93 +2.20% 13,430
23/04/24 0.91 0.00% 510
22/04/24 0.91 +1.08% 17,356

Delayed Quote OTC Markets, April 26, 2024 at 06:02 pm

More quotes

Company Profile

Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.
Sector
Biotechnology & Medical Research
Calendar
08/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRESH TRACKS THERAPEUTICS, INC. Stock Fresh Tracks Therapeutics, Inc.
+3.53% 5.44M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. FRTX Stock